胎盘质膜脂肪酸结合蛋白与非妊娠糖尿病巨大儿发生的关联性

Abstract
Figure/Table
References (0)
Related Citation (12)

Download: PDF (1369 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the association between the expression level of placental plasma membrane fatty acid binding protein (FABPpm) and non-gestational diabetes mellitus (non-GDM) macrosomia.Methods: A case-control study was performed. Forty macrosomia newborns (birth weight≥4 000 g) with normal pregnancy and full-term delivery were collected as case group from June 2015 to June 2016 continuously in the obstetric department of the Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University. And 40 normal-birth-weight newborns (birth weight ranging from 2 500 to 3 999 g) were randomly selected as control group from those delivered within 3 days of macrosomia delivery. Self-designed questionnaires were used to collect maternal and fetal information, the placenta and cord blood samples were obtained. We detected the placental mRNA and protein expression levels of FABPpm by real-time quantitative PCR and western blotting, and determined the non-esterified fatty acids levels in umbilical cord blood by colorimetry. Logistic regression analysis was used to analyze the influencing factors of macrosomia. Results: The expression levels of FABPpm mRNA and protein in the placenta of macrosomia group were higher than those of control group (P<0.05). The FABPpm mRNA expression in placenta was positively correlated with birth weight in both groups (control group: rs=0.337, P=0.033; macrosomia group: rs=0.493, P=0.002). And FABPpm mRNA expression was positively correlated with NEFA level of umbilical cord blood in the control group (rs=0.334, P=0.046), but not in the macrosomia group. Multivariate logistic regression analysis showed that the higher FABPpm expression in placenta could increase the risk of macrosomia (OR=3.138, 95%CI=1.050-9.382, P=0.041), and the occurrence of macrosomia was also influenced by the fetal gender (OR=3.229, 95%CI=1.002-10.403, P=0.049) and gestational weight gain (OR=3.573, 95%CI=1.018-12.543, P=0.047). Conclusion: The up-regulation of FABPpm expression in placenta may increase the risk of non-GDM macrosomia, suggesting that FABPpm may affect the occurrence of macrosomia by affecting fatty acid transport.

Key words： plasma membrane fatty acid-binding protein macrosomia placenta nonestesterified fatty acid

Received: 29 January 2019

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAN Ying
	WANG Chenchen
	WANG Yuhuan
	YE Yan
	YAN Hongtao
	YANG Xinjun

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2019/V49/I7/517

[1] JEFFERS E, DODDS L, ALLEN V, et al. Predicting the risk of macrosomia at mid-pregnancy among non-diabetics: a retrospective cohort study[J]. J Obstet Gynaecol Can, 2017, 39(12): 1129-1136.
[2] WANG D, HONG Y, ZHU L, et al. Risk factors and outcomes of macrosomia in China: A multicentric survey based on birth data[J]. J Matern Fetal Neonatal Med, 2017, 30(5): 623-627.
[3] MURPHY S L, XU J, KOCHANEK K D, et al. Deaths: Final Data for 2015[J]. Natl Vital Stat Rep, 2017, 66(6): 1-75.
[4] GLODEAN D, MICLEA D, POPA A. Macrosomia, A systematic review of recent literature[J]. Rom J Diabetes Nutr Metab Dis, 2018, 25(2): 187-195.
[5] YU Z B, HAN S P, ZHU G Z, et al. Birth weight and subsequent risk of obesity: a systematic review and meta-analysis [J]. Obes Rev, 2011, 12(7): 525-542.
[6] HERMANN G M, DALLAS L M, HASKELL S E, et al. Neonatal macrosomia is an independent risk factor for adult metabolic syndrome[J]. Neonatology, 2010, 98(3): 238-244.
[7] PUNDIR J, SINHA P. Non-diabetic macrosomia: An obstetric dilemma[J]. J Obstet Gynaecol, 2009, 29(3): 200-205
[8] HERRERA E, DESOYE G. Maternal and fetal lipid metabolism under normal and gestational diabetic conditions[J]. Horm Mol Biol Clin Investig, 2016, 26(2): 109-127.
[9] O' TIERNEY-GINN P F, GILLINGHAM M, FOWLER J, et al. Maternal weight gain regulates Omega-3 fatty acids in male, not female, neonates[J]. Reprod Sci, 2017, 24(4): 560-567.
[10] HAGGARTY P. Fatty acid supply to the human fetus[J]. Annu Rev Nutr, 2010, 30: 237-255.
[11] 王晨晨, 李一美, 孙昊, 等. 胎盘FAT/CD36表达与巨大儿发生的相关性[J]. 温州医科大学学报, 2017, 47(6): 416-420.
[12] CAMPBELL F M, TAFFESSE S, GORDON M J, et al. Plasma membrane fatty-acid-binding protein in human placenta: identification and characterization[J]. Biochem Biophys Res Commun, 1995, 209(3): 1011-1017.
[13] DUTTA-ROY A K. Cellular uptake of long-chain fatty acids: role of membrane-associated fatty-acid-binding/transport proteins[J]. Cell Mol Life Sci, 2000, 57(10): 1360-1372.
[14] Rasmussen K M, Yaktine A L. Weight gain during pregnancy: reexamining the guidelines[M]. Washington DC: The National Academies Press, 2009.
[15] RANI A, WADHWANI N, CHAVAN-GAUTAM P, et al. Altered development and function of the placental regions in preeclampsia and its association with long-chain polyunsaturated fatty acids[J]. Wiley Interdiscip Rev Dev Biol, 2016, 5(5): 582-597.
[16] NICKERSON J G, ALKHATEEB H, BENTON C R, et al.
Greater transport efficiencies of the membrane fatty acid transporters FABPpm and FATP4 compared with FABPpm and FATP1 and differential effects on fatty acid esterification and oxidation in rat skeletal muscle[J]. J Biol Chem, 2009, 284(24): 16522-16530.
[17] CLARKE D C, MISKOVIC D, HAN X X, et al. Overexpression of membrane-associated fatty acid binding protein (FABPpm) in vivo increases fatty acid sarcolemmal transport and metabolism[J]. Physiol Genomics, 2004, 17(1): 31-37.
[18] BRASS E, HANSON E, O’TIERNEY-GINN P F. Placental oleic acid uptake is lower in male offspring of obese women [J]. Placenta, 2013, 34(6): 503-509.
[19] Simental-Mendía L E, Castañeda-Chacón A, Rodríguez-Morán M, et al. Birth-weight, insulin levels, and HOMA-IR in newborns at term[J]. BMC Pediatr, 2012, 12: 94.
[20] KOYANAGI A, ZHANG J, DAGVADORJ A, et al. Macrosomia in 23 developing countries: an analysis of a multicountry, facility-based, cross-sectional survey[J]. Lancet, 2013, 381(9865): 476-483.